Keros Therapeutics, Inc. SEC filings KROS

Keros Therapeutics, Inc. has 536 filings in SEC EDGAR's recent list, going back to Apr 29, 2016. Its latest annual report, Form ARS, was filed on Apr 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.

Keros Therapeutics, Inc. SEC filings
Form Description Filed Period
ARS Annual report to shareholders Apr 22, 2026 Dec 31, 2025
10-K Annual report Mar 4, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 23, 2025 Dec 31, 2024
10-K Annual report Feb 26, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 17, 2024 Dec 31, 2023
10-K Annual report Feb 28, 2024 Dec 31, 2023
ARS Annual report to shareholders Apr 24, 2023 Dec 31, 2022
10-K Annual report Mar 3, 2023 Dec 31, 2022
10-K Annual report Mar 9, 2022 Dec 31, 2021
10-K Annual report Mar 25, 2021 Dec 31, 2020

Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
KROS (Nasdaq)
Fiscal year ends
December 31
Headquarters
Lexington, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1664710

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.